ArticleUltrasonography (Seoul, Korea)2026
The role of transabdominal ultrasound in pancreatic cyst surveillance: correlation with cross-sectional imaging findings and malignancy risk.
Article in Ultrasonography (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transabdominal ultrasonography as an alternative modality for pancreatic cyst surveillance: potentials and limitations.Ultrasonography (Seoul, Korea) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to evaluate the clinical utility of transabdominal ultrasound (TAUS) for pancreatic cyst surveillance by assessing its concordance with follow-up computed tomography (CT) and magnetic resonance imaging (MRI) findings and the associated risk of malignancy.
methodsThis retrospective study included 523 patients who underwent TAUS for pancreatic cysts (≥1 cm), followed by contrast-enhanced CT or MRI within a 1-year interval between 2021 and 2022. Cysts were classified as high-risk if they exhibited any high-risk stigmata or worrisome features, and as low-risk otherwise, based on the 2024 international consensus guidelines. TAUS classifications were compared with those from CT/MRI. In a subset of 164 patients with reference standards, malignancy rates were compared between high- and low-risk cysts on TAUS.
resultsThe overall cyst identification rate on TAUS was 88.7% (464/523), with identification rates higher in patients with lower body mass index (23.8±3.3 kg/m2 vs. 29.2±3.3 kg/m2, P=0.003) and in those with non-tail cyst locations (92.7% [406/438] vs. 68.2% [58/85] for tail lesions, P<0.001). Among identified cysts, 86 (18.5%) were classified as high-risk and 378 (81.5%) as low-risk. TAUS-based risk classification demonstrated significant correlation with CT/MRI classification (P<0.001). The likelihood of a high-risk cyst on CT/MRI increased with the number of high-risk or worrisome features identified on TAUS. Malignancy rates were significantly higher in high-risk cysts than in low-risk cysts based on TAUS assessment (12.5% [4/32] vs. 1.5% [2/132], P=0.014).
conclusionTAUS may serve as a useful noninvasive imaging modality for pancreatic cyst surveillance, particularly in patients with favorable visualization conditions. TAUS features correlated well with CT/MRI findings in identifying high-risk pancreatic cysts, and the presence of multiple worrisome features on TAUS was associated with an increased likelihood of high-risk classification on subsequent cross-sectional imaging.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.